Holen Sie sich die Stockscreener-App
6.08
3.93%
0.23
Entrada Therapeutics Inc Aktie (TRDA) Neueste Nachrichten
Entrada Therapeutics Inc (TRDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Entrada Therapeutics Inc (TRDA) Cash Flow - TradingKey
Entrada Therapeutics Inc (TRDA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Entrada Therapeutics Inc (TRDA) Institutional Confidence - TradingKey
Entrada Therapeutics Inc (TRDA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Entrada Therapeutics Inc (TRDA) Balance Sheet - TradingKey
Entrada Therapeutics Inc (TRDA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Why (TRDA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Entrada Therapeutics Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Mild Stock UptickBanking Earnings Report - dars.gov.et
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates - MSN
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Entrada Therapeutics (TRDA) Gains 4.6% as Biotech Stock Tests Key Resistance Near $7.47Bullish Sentiment - dars.gov.et
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewir - The National Law Review
Entrada Therapeutics (TRDA) Slips 4.5% as Stock Tests Key Support ZoneInvestment Factor - dars.gov.et
Entrada Therapeutics, Inc.(NasdaqGM: TRDA) dropped from Russell 2000 Defensive Index - marketscreener.com
Understanding Momentum Shifts in (TRDA) - Stock Traders Daily
Price to book forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView
Price to earnings forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView
Price to sales forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView
Enterprise value to revenue forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView
Entrada Therapeutics Inc Actuals & Estimates (NASDAQ:TRDA) - TradingView
TRDA Forecast — Price Target — Prediction for 2027 - TradingView
Entrada Therapeutics (TRDA) Declines Nearly 5% as Stock Tests Key Support at $6.81Earnings Quality Factor - dars.gov.et
Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Entrada Therapeutics (TRDA) Surges 4.11% as Shares Test Resistance Near $7.44Liquidity Sweep - dars.gov.et
TRDA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Entrada Therapeutics Inc (TRDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Avoiding Lag: Real-Time Signals in (TRDA) Movement - Stock Traders Daily
Entrada Therapeutics Inc (TRDA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Entrada Therapeutics Inc (TRDA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity - Stock Titan
Entrada Therapeutics (TRDA) awards director 19,000 options at $5.97 - Stock Titan
Entrada Therapeutics director granted 19,000 options | TRDA Insider Trading - Stock Titan
Entrada Therapeutics (TRDA) director receives 19,000-share stock option grant - Stock Titan
Entrada Therapeutics (TRDA) director receives grant of 19,000 stock options - Stock Titan
Entrada Therapeutics (TRDA) Gains Ground: Modest Rally Tests Key Resistance LevelsDay Trade Opportunities - newsline.com
Entrada Therapeutics Stockholders Approve Directors and Equity Plans - The Globe and Mail
[8-K] Entrada Therapeutics, Inc. Reports Material Event - Stock Titan
Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE) - The Globe and Mail
Entrada Therapeutics Inc. (TRDA) Q1 2026 Earnings: Narrower Loss Surprises, but No Revenue Weighs on SharesROIC Trend Report - newsline.com
Entrada Therapeutics (TRDA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Entrada Therapeutics Inc. (TRDA) Faces Selling Pressure as Shares Dip to $6.20Triple Top - dars.gov.et
Discipline and Rules-Based Execution in TRDA Response - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc.TRDA - PR Newswire
Oppenheimer Remains a Buy on Entrada Therapeutics Inc (TRDA) - The Globe and Mail
TRDA: Strong safety and early efficacy in DMD trials drive confidence in a growing clinical pipeline - TradingView
Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Safety committee approves higher 10 mg/kg dose for Entrada's Duchenne muscular dystrophy trial - Pluang
Entrada gets clearance to escalate dose in DMD trial By Investing.com - Investing.com South Africa
Entrada gets clearance to escalate dose in DMD trial - Investing.com
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study - The Manila Times
Rare disease trial tests DMD treatment with once-every-six-week dosing - Stock Titan
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):